How Do Compartmentalized Lung Subphenotypes in Pneumonia Affect Critical Care?

By
Andrew Conway Morris
Shyamanova Mazumdar
Mark Jeffrey
October 28, 2026

Intensive Care Medicine

At a Glance

Category	Detail
Condition	Pulmonary inflammatory subphenotypes (pneumotypes) identified in patients with suspected pneumonia
Key Mechanisms	BAL-cell transcriptomic analysis identified Pn1, described as immunologically silent and relatively hypoinflammatory; Pn2, with a balanced immune response; and Pn3, hyperinflammatory with immature-neutrophil signatures.
Target Population	Patients with suspected pneumonia studied using bronchoalveolar lavage, including cohorts with severe pneumonia
Care Setting	Research characterization of pulmonary inflammation using bronchoalveolar lavage; the commentary discusses relevance to critical care

Key Highlights

Transcriptomic analysis of bronchoalveolar lavage cells identified three pulmonary phenotypes that were not detectable in blood.
The poorest outcomes occurred when low pulmonary inflammation coincided with a more inflammatory blood signature.
Pn1 was associated with severe respiratory failure and common alveolar haemorrhage despite low alveolar cytokines and sparse neutrophils; proposed surfactant-processing mechanisms remain unconfirmed.
Pn2 was associated with the most favorable outcomes, strong epithelial-repair signatures, earlier ventilator liberation, and the lowest mortality.
Pn3 featured elevated cytokines, neutrophil and monocyte infiltration, and genetic signatures of neutrophil immaturity; the authors discuss self-reinforcing inflammatory cycles as a possible explanation for persistent injury.

Guideline-Based Recommendations

Diagnosis

The commentary describes research pneumotypes identified by transcriptomic analysis of bronchoalveolar lavage cells; it does not report a clinically validated diagnostic classifier.

Management

The commentary does not establish pneumotype-directed treatment recommendations.

Monitoring & Follow-up

The reported pulmonary pneumotypes were not detectable in blood, although pulmonary and blood IL-6 levels were correlated in the source text.
Patients classified as Pn2 achieved ventilator liberation sooner than patients with the other phenotypes; this is a reported outcome, not monitoring guidance.

Risks

The authors caution that blood phenotypes may fail to represent pulmonary inflammation, potentially leading to inappropriate application of therapies.
Pn1 was associated with alveolar haemorrhage and severe respiratory failure despite relatively low alveolar cytokines and sparse neutrophils.
The authors propose that self-reinforcing inflammatory cycles may contribute to persistent lung injury in Pn3.

Patient & Prescribing Data

Patients with suspected pneumonia studied using bronchoalveolar lavage, including cohorts with severe pneumonia; Pn1 was more frequent among immunosuppressed patients, although 44% of affected individuals were not immunosuppressed.

The commentary provides no prescribing guidance. It reports that pulmonary inflammation and injury may continue after pathogen clearance despite appropriate antibiotics, prompting ongoing or intensified antimicrobial treatment.

Clinical Best Practices

The authors report that pulmonary pneumotypes were not detectable in blood; they caution that blood phenotypes may not represent pulmonary inflammation.
The authors describe Pn1 surfactant-processing mechanisms as proposed and in need of further investigation.
The pneumotypes are research findings; the commentary does not establish a clinically validated classifier or phenotype-directed treatment recommendations.